| Dr Kathryn Claire Eisermann-rogers, MD | |
|
6705 Sw 57th Ave, Suite 318, Coral Gables, FL 33143-3638 | |
| (305) 665-1623 | |
| (305) 666-9176 |
| Full Name | Dr Kathryn Claire Eisermann-rogers |
|---|---|
| Gender | Female |
| Speciality | Allergy/immunology |
| Experience | 42 Years |
| Location | 6705 Sw 57th Ave, Coral Gables, Florida |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306865472 | NPI | - | NPPES |
| 6638275-004 | Other | FL | CIGNA |
| 003GX | Other | FL | PREFERRED CARE PARTNERS |
| 001906BAPT | Other | FL | NHP |
| 09876 | Other | FL | BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | ME53004 (Florida) | Primary |
| Entity Name | Kathryn Eisermann Rogers Md Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013953165 PECOS PAC ID: 8527026079 Enrollment ID: O20041229001025 |
News Archive
Two University of Rhode Island associate professors, biophysicists Yana Reshetnyak and Oleg Andreev, have discovered a technology that can detect cancerous tumors and deliver treatment to them without the harming the healthy cells surrounding them, thereby significantly reducing side effects.
Stem cells are heavily studied around the world with the hope to revive damaged body parts unable to regenerate itself. Injured heart muscles are one of these areas which remain impaired in adults who have experienced heart attacks.
Innovators at Purdue University have received new support as they work to develop solutions to what U.S. military officials call an alarming trend in dementia among wounded soldiers. The same researchers also seek solutions to better treat Alzheimer's disease.
Medtronic, Inc., announced that the Symplicity renal denervation system provides safe, significant and sustained blood pressure reduction up to three years in patients with treatment-resistant hypertension, according to data from two clinical trials presented at the 2012 American College of Cardiology (ACC) meeting.
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced topline results from a Phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class Hedgehog pathway inhibitor. GDC-0449 was tested in combination with Avastin® (bevacizumab) and FOLFOX or FOLFIRI chemotherapy in first-line metastatic colorectal cancer patients.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kathryn Claire Eisermann-rogers, MD 7800 Sw 87th Ave Ste C-340, Miami, FL 33173-3570 Ph: (305) 595-0109 | Dr Kathryn Claire Eisermann-rogers, MD 6705 Sw 57th Ave, Suite 318, Coral Gables, FL 33143-3638 Ph: (305) 665-1623 |
News Archive
Two University of Rhode Island associate professors, biophysicists Yana Reshetnyak and Oleg Andreev, have discovered a technology that can detect cancerous tumors and deliver treatment to them without the harming the healthy cells surrounding them, thereby significantly reducing side effects.
Stem cells are heavily studied around the world with the hope to revive damaged body parts unable to regenerate itself. Injured heart muscles are one of these areas which remain impaired in adults who have experienced heart attacks.
Innovators at Purdue University have received new support as they work to develop solutions to what U.S. military officials call an alarming trend in dementia among wounded soldiers. The same researchers also seek solutions to better treat Alzheimer's disease.
Medtronic, Inc., announced that the Symplicity renal denervation system provides safe, significant and sustained blood pressure reduction up to three years in patients with treatment-resistant hypertension, according to data from two clinical trials presented at the 2012 American College of Cardiology (ACC) meeting.
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced topline results from a Phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class Hedgehog pathway inhibitor. GDC-0449 was tested in combination with Avastin® (bevacizumab) and FOLFOX or FOLFIRI chemotherapy in first-line metastatic colorectal cancer patients.
› Verified 1 days ago
Michel Elias Akl, M.D. Allergy & Immunology Medicare: May Accept Medicare Assignments Practice Location: 806 S Douglas Rd Ste 101, Coral Gables, FL 33134 Phone: 305-223-3577 Fax: 305-552-7940 | |
Dr. Miguel J Lanz, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 365 Alcazar Ave, Coral Gables, FL 33134 Phone: 305-445-0441 | |
Dr. Frank J. Martell, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 475 Biltmore Way, Ste 311, Coral Gables, FL 33134 Phone: 305-445-9422 Fax: 305-444-4651 |